Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linerixibat - GSK

Next Previous
Drug Profile

Linerixibat - GSK

Alternative Names: GSK 2330672; GSK 672

Latest Information Update: 10 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Antihyperglycaemics; Antipruritics; Benzene derivatives; Carboxylic acids; Ethers; Small molecules; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pruritus
  • Phase II Primary biliary cirrhosis; Type 2 diabetes mellitus
  • No development reported Cholestasis

Most Recent Events

  • 20 Dec 2024 GlaxoSmithKline completes the phase III trial for Pruritus (In adults, In the elderly) (PO, Tablet) in US, Argentina, Belgium, Japan, Mexico, Poland, Russia, Italy, Brazil, Bulgaria, Canada, China, Czech Republic, France, Germany, Greece, Israel, Spain, Switzerland and UK(NCT04950127)
  • 10 Nov 2023 Pharmacodynamics data from the phase II GLIMMER trial in Pruritus presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 06 Dec 2022 GlaxoSmithKline completes a phase I trial for Pruritus (In volunteers) in USA (NCT05393076)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top